proport
critic
ill
patient
defici
immun
system
risen
recent
year
third
icu
admiss
immunocompromis
patient
includ
patient
receiv
longterm
month
highdos
mgkgday
steroid
immunosuppress
drug
solidorgan
transplant
recipi
patient
solid
tumor
requir
chemotherapi
last
year
hematolog
malign
whatev
time
sinc
diagnosi
receiv
treatment
patient
primari
immun
defici
patient
aid
discuss
anoth
manuscript
issu
factor
contribut
trend
includ
increas
aggress
durat
cancer
treatment
greater
use
organ
hematopoiet
cell
transplant
introduct
treatment
autoimmun
autoinflammatori
diseas
steroidspar
agent
induc
specif
immun
defect
thu
larg
number
patient
expect
live
mani
year
immun
defici
put
risk
sever
infect
sever
respiratori
infect
lead
reason
intens
care
unit
icu
admiss
immunocompromis
patient
risk
hypoxem
acut
respiratori
failur
arf
sepsi
lifesupport
intervent
must
implement
time
extens
investig
conduct
identifi
caus
pulmonari
involv
failur
identifi
etiolog
arf
associ
higher
risk
die
moreov
identifi
pathogen
crucial
antimicrobi
stewardship
immunocompromis
patient
howev
etiolog
diagnosi
extrem
challeng
effect
infect
combin
underli
diseas
treatment
creat
extraordinarili
complex
clinic
pictur
addit
patient
one
concurr
infect
other
noninfecti
caus
arf
mimic
infect
furthermor
fiberopt
bronchoscopi
bronchoalveolar
lavag
fobbal
commonli
use
diagnosi
may
caus
respiratori
deterior
patient
hypoxemia
develop
noninvas
diagnost
test
high
sensit
specif
eg
blood
plasma
sputum
urin
nasal
swab
obviat
need
fobbal
patient
util
noninvas
test
evalu
hope
provid
clinician
addit
tool
diagnosi
complex
patient
review
summar
contemporari
literatur
clinic
practic
guidelin
regard
diagnost
test
sever
respiratori
infect
immunocompromis
critic
ill
patient
addit
briefli
discuss
ongo
research
treatment
outcom
search
pubm
cochran
databas
relev
articl
publish
use
human
english
languag
filter
main
search
term
respiratori
infect
pneumonia
opportunist
infect
bacteri
infect
fungal
infect
viral
infect
parasit
infect
addit
search
term
immunocompromis
cancer
transplant
steroid
immunosuppress
drug
identifi
public
epidemiolog
outcom
diagnosi
acut
respiratori
failur
icu
intens
care
critic
care
critic
ill
retriev
public
icu
manag
immunocompromis
patient
arf
addit
articl
identifi
internet
search
use
term
arf
immunocompromis
patient
may
due
infect
one
viral
bacteri
fungal
parasit
agent
addit
noninfecti
factor
may
contribut
caus
arf
sought
routin
factor
discuss
review
includ
radiat
drugrel
pulmonari
toxic
diffus
alveolar
hemorrhag
pulmonari
edema
lung
lesion
due
underli
diseas
eg
leukem
infiltr
engraft
syndrom
gvhd
lymphangit
carcinomatosi
pulmonari
vascul
exist
guidelin
manag
lung
diseas
critic
ill
immunocompromis
patient
emphas
import
obtain
valid
diagnost
sampl
howev
antimicrobi
therapi
often
start
immedi
sampl
collect
result
caus
pathogen
identifi
half
patient
bacteri
pneumonia
detail
analysi
clinic
laboratori
imagingstudi
find
provid
valuabl
diagnost
orient
case
nevertheless
frequenc
bacteri
pneumonia
probabl
underestim
mani
case
atyp
therefor
escap
recognit
hand
noninfecti
pulmonari
abnorm
may
mistakenli
diagnos
clinic
document
infect
basic
rule
shown
tabl
provid
help
guidanc
determin
caus
pulmonari
infiltr
select
appropri
diagnost
strategi
immunocompromis
patient
arf
first
step
etiolog
evalu
clinic
assess
advoc
use
mnemon
direct
tabl
base
day
sinc
respiratori
symptom
onset
type
immunodefici
fig
radiograph
pattern
experi
assess
clinician
clinic
find
highresolut
comput
tomographi
hrct
find
fig
variabl
easili
evalu
bedsid
analysi
usual
restrict
number
possibl
etiolog
two
three
addit
invas
noninvas
investig
obtain
need
diagnost
strategi
tailor
pretest
probabl
diseas
sought
govern
diagnost
yield
importantli
indic
fobbal
chang
avoid
expos
patient
potenti
advers
event
tabl
fobbal
consid
mandatori
perform
optim
monitor
highflow
oxygen
therapi
use
correct
hypoxemia
risk
intub
assess
care
associ
higher
mortal
introduct
noninvas
test
notabl
base
nextgener
sequenc
ng
transcriptom
proteom
may
reduc
need
fobbal
updat
research
need
howev
determin
exact
diagnost
yield
critic
ill
immunocompromis
patient
hypoxem
arf
diagnost
perform
bal
report
specif
case
vignett
arf
bilater
groundglass
opac
organ
transplant
recipi
oppos
illdefin
alveolar
consolid
neutropen
patient
febril
arf
specif
arf
etiolog
bacteri
infect
oppos
invas
fungal
infect
patient
suspect
arf
either
infecti
noninfecti
origin
ie
drugrel
pulmonari
toxic
pulmonari
infiltr
underli
diseas
etc
bacteri
pneumonia
account
icu
admiss
cancer
patient
depend
type
immunosuppress
incid
rate
vari
chemotherapi
lung
cancer
chemotherapi
acut
leukemia
incid
rate
lung
transplant
heart
liver
transplant
renal
transplant
splenectomi
also
increas
rel
risk
develop
pneumonia
particularli
encapsul
bacteria
pneumococc
meningococc
haemophilu
influenza
vaccin
indic
patient
splenectomi
type
immunosuppress
risk
factor
classic
bacteri
pneumonia
patient
hospit
communityacquir
pneumonia
cap
immunocompromis
longterm
steroid
therapi
mgday
prednisoneequival
month
main
caus
immunosuppress
neutropenia
also
associ
higher
risk
bacteri
pneumonia
notabl
profound
prolong
neutrophil
day
critic
ill
cancer
patient
sever
pneumonia
neutropenia
lymphopenia
also
associ
increas
risk
pneumonia
humor
immunosuppress
hypogammaglobulinemia
risk
factor
bacteri
pneumonia
especi
streptococcu
pneumonia
haemophilu
influenza
addit
immunosuppress
patient
may
factor
associ
bacteri
pneumonia
pseudomona
pneumonia
structur
lung
diseas
chronic
obstruct
pulmonari
diseas
copd
bronchiectasi
diabet
mellitu
smoke
alcohol
abus
specif
risk
factor
report
pneumonia
due
nocardia
neisseria
rhodococcu
q
fever
coxiella
burnetii
nocardiosi
associ
hematolog
solid
malign
highdos
steroid
therapi
antagonist
therapi
risk
factor
n
meningitidi
infect
nasopharyng
carriag
complement
defici
rhodococcu
pneumonia
report
recipi
hematopoiet
stem
cell
solid
organ
legionella
describ
cancer
patient
well
take
system
corticosteroid
biolog
therapi
bacteri
pneumonia
consid
patient
present
nonspecif
symptom
eg
cough
dyspnea
fever
sputum
product
pleurit
chest
pain
pulmonari
infiltr
howev
symptom
often
blunt
patient
immun
defici
bacteri
pneumonia
may
complic
septic
shock
andor
acut
respiratori
distress
syndrom
chest
radiograph
hrct
find
specif
includ
lobar
consolid
alveolar
interstiti
infiltr
cavit
andor
pleural
effus
extrapulmonari
manifest
suggest
infect
legionella
nocardia
nocardia
dissemin
bloodstream
skin
bone
joint
retina
heart
andor
central
nervou
system
streptococcu
pneumonia
klebsiella
pneumonia
haemophilu
spp
frequent
identifi
caus
pathogen
pseudomona
spp
enter
gramneg
bacilli
stenotrophomona
spp
methicillinresist
staphylococcu
aureu
consid
multidrugresist
mdr
pathogen
significantli
common
immunocompromis
patient
one
studi
respons
ventilatorassoci
lower
respiratori
tract
infect
data
scarc
mycoplasma
legionella
chlamydia
speci
popul
routin
noninvas
test
bacteri
pneumonia
includ
sputum
sampl
blood
cultur
urin
antigen
detect
sputum
gram
stain
rare
inform
yield
sputum
bacteri
cultur
low
although
improv
optim
sampl
absenc
prior
antibiot
therapi
endotrach
aspir
like
recov
caus
organ
expector
sputum
organ
recov
immedi
intub
unlik
reflect
mere
colon
patient
malign
arf
randomizedcontrol
trial
report
strategi
noninvas
test
includ
sputum
sampl
inferior
fobbal
patient
admit
cap
urin
antigen
detect
sensit
specif
pneumonia
correspond
valu
l
pneumophila
blood
cultur
also
low
yield
patient
admit
cap
although
higher
yield
report
pulmonari
involv
sever
bacteri
identif
polymeras
chain
reaction
pcr
respiratori
sampl
report
provid
sensit
may
superior
standard
cultur
patient
cap
especi
previous
given
antibiot
diagnost
yield
pleural
fluid
cultur
reach
blood
cultur
bottl
use
diagnosi
nocardiosi
requir
specif
cultur
media
pcr
n
meningitidi
infect
diagnos
base
blood
cerebrospin
fluid
cultur
rhodococcu
grow
readili
ordinari
media
serolog
test
cornerston
diagnosi
q
fever
realtim
pcr
rtpcr
produc
quantit
inform
help
distinguish
colon
infect
pcr
use
detect
resist
gene
therebi
guid
initi
antibiot
treatment
new
tool
ng
develop
identifi
bacteria
fungi
virus
respiratori
sampl
may
improv
diagnosi
concomit
infect
realtim
metagenom
also
hold
promis
rapidli
identifi
pathogen
caus
bacteri
pneumonia
initi
empir
treatment
pneumonia
follow
clinic
practic
guidelin
local
resist
pattern
sever
pneumonia
immunocompromis
patient
still
often
fatal
studi
cancer
septic
hospit
mortal
rate
risk
activ
tuberculosi
increas
patient
immun
impair
hiv
diabet
cancer
solidorgan
transplant
sot
receiv
system
steroid
antagonist
therapi
symptom
mycobacteri
infect
insidi
compar
cap
includ
persist
cough
lymphadenopathi
fever
night
sweat
weight
loss
immunocompromis
patient
may
one
mild
symptom
persist
fever
even
though
dissemin
organ
outsid
lung
common
hrct
find
includ
miliari
nodul
cavit
centrilobular
treeinbud
nodul
consolid
mediastin
lymphadenopathi
pleural
effus
cavit
centrilobular
treeinbud
nodul
often
locat
upper
lobe
diagnosi
pulmonari
tuberculosi
base
demonstr
acidfast
bacilli
three
induc
sputum
sampl
smear
cultur
singl
fob
specimen
cultur
requir
medium
pcr
test
done
first
sampl
falseneg
cultur
common
pcr
test
sputa
report
sensit
specif
overal
correspond
valu
patient
neg
sputum
smear
find
pcr
may
lower
yield
hivneg
hivposit
immunocompromis
patient
adenosin
deaminas
marker
tuberculosi
measur
pleural
fluid
releas
assay
igra
tuberculin
skin
test
tst
serv
detect
latent
tuberculosi
combin
tuberculosi
drug
must
given
suggest
steroid
therapi
might
decreas
mortal
critic
ill
patient
tuberculosi
arf
although
data
need
mortal
rate
patient
tuberculosi
arf
rang
nontubercul
mycobacteria
ntm
speci
mycobacteria
tuberculosi
lepra
ntm
gener
freeliv
organ
ubiquit
environ
date
ntm
speci
identifi
human
diseas
due
ntm
classifi
four
clinic
syndrom
chronic
pulmonari
diseas
lymphaden
cutan
diseas
dissemin
diseas
risk
factor
dissemin
diseas
similar
tuberculosi
includ
hiv
infect
steroid
antagonist
diabet
cancer
sot
patient
present
cough
fatigu
malais
weak
dyspnea
chest
discomfort
occasion
hemoptysi
extrapulmonari
manifest
seen
dissemin
diseas
consist
arthriti
tenosynov
skin
lesion
gastrointestin
manifest
fever
weight
loss
less
common
patient
tuberculosi
ntm
exist
environ
presenc
nonsteril
respiratori
specimen
necessarili
indic
role
caus
lung
diseas
american
thorac
societi
at
infecti
diseas
societi
america
idsa
diagnost
criteria
ntm
lung
diseas
follow
pulmonari
symptom
compat
radiograph
find
two
posit
sputum
cultur
one
posit
bal
sampl
evid
ntm
posit
lungbiopsi
cultur
compat
histolog
featur
dissemin
diseas
blood
cultur
special
media
perform
mycobacteri
cultur
must
kept
least
week
bone
marrow
fluid
tissu
sampl
suspect
site
involv
sent
cultur
histolog
examin
special
stain
treatment
reli
combin
antibiot
treatment
durat
depend
type
ntm
manifest
common
communityacquir
respiratori
virus
carv
caus
sever
potenti
fatal
arf
immunocompromis
patient
tabl
carv
includ
influenza
viru
parainfluenza
viru
piv
respiratori
syncyti
viru
rsv
rhinovirusenteroviru
human
metapneumoviru
hmpv
influenza
caus
influenza
b
virus
character
annual
season
epidem
sporad
pandem
outbreak
estim
annual
influenza
outbreak
affect
million
peopl
million
see
healthcar
provid
nearli
million
admit
hospit
among
critic
ill
patient
influenza
immunocompromis
mortal
time
high
nonimmunocompromis
patient
among
patient
admit
influenza
immunocompromis
rsv
infect
typic
season
pose
similar
seriou
risk
immunocompromis
patient
influenza
viru
rsv
infect
found
patient
undergo
hct
onethird
progress
lower
respiratori
tract
infect
fatal
case
piv
caus
respiratori
diseas
similar
seen
rsv
rsv
piv
found
nasopharyng
swab
critic
ill
hematolog
patient
respect
prospect
studi
hsct
recipi
account
viral
respiratori
infect
viru
often
acquir
commun
brought
transplant
ward
staff
may
mimic
opportunist
infect
therebi
rais
diagnost
challeng
hmpv
close
relat
rsv
often
caus
sever
infect
requir
mechan
ventil
patient
elderli
andor
comorbid
rhinovirusesenterovirus
picornavirida
circul
throughout
year
increasingli
recogn
caus
lower
respiratori
tract
infect
immunocompromis
patient
critic
ill
hematolog
patient
rhinovirusesenterovirus
preval
virus
detect
icu
admiss
risk
factor
viral
pneumonia
overlap
bacteri
pneumonia
coinfect
common
patient
sever
pneumonia
steroid
therapi
hematolog
malign
lymphopenia
older
age
hct
strongli
associ
viral
infect
season
distribut
peak
winter
spring
symptom
imagingstudi
find
specif
viral
infect
overlap
occur
chang
seen
bacteri
infect
although
diffus
airspac
pattern
common
bacteri
pneumonia
main
find
treeinbud
groundglass
pattern
diagnosi
reli
identif
viru
variou
sampl
carv
identifi
cultur
serolog
rapid
diagnost
test
base
enzym
immunoassay
eia
immunofluoresc
pcr
molecular
amplif
techniqu
larg
supersed
cell
cultur
primari
mean
detect
identifi
virus
clinic
sampl
pcr
refer
standard
diagnost
test
idsa
recommend
immunocompromis
patient
present
acut
onset
respiratori
symptom
test
influenza
pcrbase
diagnost
panel
detect
multipl
respiratori
virus
simultan
within
h
new
sensit
method
increas
abil
identifi
broader
rang
virus
rhinoviru
whose
clinic
signific
care
assess
uncertainti
still
surround
type
sampl
appropri
detect
type
viru
nasalthroat
swab
bal
minib
cytopatholog
even
lung
biopsi
perform
import
consider
choos
sampl
techniqu
clinic
condit
patient
patient
receiv
mechan
ventil
endotrach
aspir
bal
fluid
collect
even
influenza
test
upper
respiratori
tract
specimen
neg
studi
pulmonolog
ward
patient
use
bal
refer
standard
nasopharyng
pcr
test
posit
neg
predict
valu
respect
viru
identifi
respiratori
tract
differenti
colon
infect
may
challeng
howev
presenc
influenza
viru
usual
indic
infect
rsv
infect
blood
test
may
help
rsvrna
detect
plasma
sampl
onethird
hsct
patient
pulmonari
rsv
infect
associ
poor
outcom
world
health
organ
center
diseas
control
prevent
cdc
recommend
oseltamivir
firstlin
agent
influenza
system
steroid
use
unless
strongli
indic
anoth
condit
patient
sever
ill
prolong
treatment
may
order
although
optim
durat
uncertain
test
antivir
resist
stage
consid
immunocompromis
patient
higher
risk
develop
resist
prolong
viral
shed
rsv
treatment
intraven
immunoglobulin
ribavirin
suggest
publish
evid
treatment
benefit
patient
recent
epidemiolog
studi
preval
carv
critic
ill
hematolog
patient
similar
gener
popul
cap
howev
presenc
carv
doubl
mortal
rate
allogen
hsct
recipi
particularli
high
risk
death
carv
infect
among
immunocompromis
patient
sever
form
influenza
onethird
requir
icu
admiss
mechan
ventil
onefifth
fatal
outcom
immunocompromis
patient
virus
commonli
respons
system
viral
infect
dna
virus
herp
virus
respons
pneumonia
includ
herp
simplex
virus
viru
vzv
cytomegaloviru
cmv
herp
virus
known
establish
lifelong
infect
often
reactiv
episod
immunosuppress
adenovirida
includ
human
adenovirus
hadv
g
produc
differ
clinic
pattern
immunocompromis
patient
hadv
caus
lifethreaten
multiorgan
damag
risk
factor
chang
time
chang
immunosuppress
viral
infect
common
patient
tcell
defici
particular
concern
take
highdos
steroid
mgday
week
receiv
tcelldeplet
allogen
hsct
treatment
alemtuzumab
fludarabin
viral
infect
may
communityacquir
opportunist
aris
due
reactiv
latent
infect
come
transplant
donor
come
transplant
recipi
eg
cmv
reactiv
seroneg
patient
receiv
solid
transplant
seroposit
donor
seroposit
recipi
receiv
hsct
seroneg
donor
endogen
reactiv
appear
predomin
caus
viral
diseas
sever
immunocompromis
patient
patient
immunosuppress
present
system
viral
infect
vari
wide
depend
caus
organ
degre
immunosuppress
tabl
lung
involv
respiratori
symptom
nonspecif
tachypnea
andor
dyspnea
hypoxia
lung
infiltr
typic
appear
crazypav
pattern
groundglass
opac
micronodul
andor
consolid
definit
diagnosi
cmv
pneumonia
requir
clinic
symptom
pneumonia
identif
cmv
lung
tissu
viru
isol
rapid
cultur
histopatholog
immunohistochemistri
dna
hybrid
techniqu
probabl
cmv
pneumonia
defin
clinic
symptom
andor
sign
pneumonia
combin
cmv
detect
viral
isol
rapid
bal
fluid
cultur
cmv
dna
quantit
bal
fluid
reliabl
cutoff
cmv
dna
load
establish
howev
furthermor
cmv
shed
may
occur
lower
respiratori
tract
cmv
dna
load
may
therefor
low
patient
asymptomat
infect
hand
neg
cmv
dna
test
bal
fluid
nearli
neg
predict
valu
therefor
exclud
cmv
pneumonia
assum
satisfactori
sampl
vzv
pneumonia
usual
readili
diagnos
base
typic
skin
rash
although
may
fail
develop
patient
sever
immunosuppress
replic
vzv
almost
alway
found
bal
fluid
hsv
pneumonia
challeng
diagnos
reactiv
blood
saliva
throat
frequent
critic
ill
patient
thu
hsv
detect
lower
airway
may
mere
indic
airway
contamin
without
parenchym
involv
diagnosi
rest
hsv
detect
bal
fluid
demonstr
specif
nuclear
inclus
bal
cell
macroscop
bronchial
lesion
may
seen
fiberopt
bronchoscopi
albeit
rare
research
need
improv
earli
detect
system
viral
infect
subclin
phase
way
immun
defici
affect
host
defens
viral
infect
need
clarif
field
treatment
optim
indic
durat
antivir
prophylaxi
better
defin
potenti
influenc
new
immunotherapeut
moleculartarget
approach
emerg
system
viral
infect
assess
use
quantit
realtim
pcr
biopsi
bal
fluid
focu
activ
research
may
allow
differenti
cmv
pneumonia
colon
antivir
drug
immunomodul
main
treatment
tool
three
import
caus
fungal
pulmonari
infect
pneumocysti
jirovecii
aspergillu
spp
cryptococcu
spp
pneumocysti
jirovecii
airborn
pathogen
transmit
asymptomat
carrier
immunocompromis
host
main
risk
factor
treatment
impair
tcell
immun
includ
steroid
acut
lymphocyt
leukemia
hsct
sot
number
primari
immunodefici
aspergillu
spp
mold
caus
infect
lung
sinus
risk
factor
consist
chiefli
sever
prolong
neutropenia
acut
myeloid
leukemia
hsct
highdos
steroid
therapi
drug
condit
chronic
impair
tcell
respons
invas
aspergillosi
ia
common
patient
expos
heavi
fungal
load
instanc
construct
site
cumul
incid
ia
month
sot
one
studi
highest
lung
transplant
recipi
hsct
recipi
incid
month
cryptococcu
spp
yeast
affect
lung
central
nervou
system
patient
impair
cellmedi
respons
c
neoforman
c
gattii
account
case
cryptococcosi
reactiv
dormant
organ
probabl
main
mechan
lung
involv
risk
factor
pulmonari
cryptococcosi
includ
malign
hsct
sot
cirrhosi
chronic
kidney
diseas
chronic
lung
diseas
diabet
treatment
steroid
antagonist
sot
recipi
cryptococcosi
account
invas
fungal
infect
overal
incid
mucoral
caus
aggress
invas
infect
patient
hematolog
malign
hsct
recipi
fusarium
mostli
affect
patient
hematolog
malign
hsct
recipi
involv
lung
sinus
pulmonari
fungal
infect
shown
tabl
patient
pulmonari
fungal
infect
present
nonspecif
symptom
fever
cough
dyspnea
pleurit
pain
andor
hemoptysi
extrapulmonari
symptom
may
help
suspect
invas
fungal
diseas
ia
hrct
show
macronodul
halo
sign
pleuralbas
wedgeshap
consolid
mass
mucormycosi
ia
share
clinic
radiolog
find
mucormycosi
suspect
presenc
sinu
involv
prior
voriconazol
therapi
revers
halo
sign
hrct
p
jirovecii
pneumonia
hrct
show
bilater
groundglass
opac
predomin
apic
spare
peripheri
common
find
pulmonari
cryptococcosi
solitari
spars
welldefin
noncalcifi
nodul
often
pleuralbas
invas
fungal
infect
ifi
classifi
proven
sign
infect
fungu
identifi
histopatholog
cytopatholog
cultur
probabl
base
host
factor
clinic
criteria
microscopi
cultur
galactomannan
antigen
gm
possibl
base
host
factor
clinic
criteria
diagnosi
p
jirovecii
pneumonia
pjp
reli
identif
pathogen
immunofluoresc
quantit
pcr
bal
fluid
ideal
induc
sputum
otherwis
serum
bdg
test
help
difficult
case
discrep
clinic
pictur
pcr
find
make
differ
colon
infect
pcr
find
gray
zone
studi
hivneg
immunocompromis
patient
quantit
pcr
bal
fluid
sensit
specif
help
differenti
infect
colon
accord
metaanalysi
serum
bdg
assay
sensit
specif
ia
figur
bal
microscopi
cultur
show
branch
septat
hypha
aspergillu
spp
grow
day
cultur
yield
low
ia
suspect
patient
high
risk
due
hematolog
malign
hsct
sot
serum
aspergillu
pcr
gm
test
recommend
fig
pcr
gm
test
may
perform
better
bal
fluid
serum
although
fobbal
done
indic
care
riskbenefit
assess
serum
bdg
test
recommend
highrisk
patient
specif
ia
systemat
review
found
sensit
specif
diagnos
ia
serum
gm
serum
bdg
compar
sensit
specif
pcr
mucormycosi
diagnos
sampl
microscopi
cultur
andor
histopatholog
immunohistochemistri
sensit
specif
mucoral
fungi
contain
neither
bdg
gm
neg
result
test
patient
whose
hrct
find
consist
ifi
therefor
suggest
mucormycosi
howev
concomit
aspergillu
infect
possibl
diagnosi
cryptococcu
pneumonia
whether
isol
central
nervou
system
involv
reli
visual
pathogen
microscopi
cultur
cerebrospin
fluid
blood
andor
sputum
cryptococcu
grow
within
day
cryptococc
antigen
assay
less
sensit
hivneg
hivposit
patient
valu
report
hivneg
immunocompromis
patient
cryptococcu
pneumonia
pjp
treat
trimethoprimsulfamethoxazol
addit
steroid
therapi
sever
form
current
recommend
hivneg
patient
assess
randomizedcontrol
trial
ia
treat
voriconazol
firstlin
treatment
mucormycosi
liposom
amphotericin
b
although
isavuconazol
constitut
valid
altern
sever
cryptococcu
pneumonia
requir
amphotericin
b
flucytosin
follow
fluconazol
fusarium
infect
manag
voriconazol
amphotericin
b
new
diagnost
method
develop
allow
earlier
diagnosi
greater
sensit
patient
fungal
infect
assay
mucoralesspecif
antigen
cell
mucoral
pcr
shown
good
sensit
specif
earlier
posit
compar
cultur
patient
ifi
mass
spectrometri
detect
panfung
serum
disaccharid
sensit
diagnos
invas
candidiasi
ia
respect
higher
specif
respect
mucormycosi
test
made
similar
contribut
diagnosi
quantit
pcr
although
surviv
improv
time
ia
remain
often
fatal
complic
hsct
retrospect
studi
patient
hematolog
malign
develop
arf
due
ia
mortal
mortal
transplant
recipi
higher
rate
hsct
sot
pjp
often
fatal
hivneg
hivposit
patient
hivneg
patient
mortal
vari
wide
depend
underli
diseas
final
mortal
rate
report
patient
pulmonari
mucormycosi
mani
parasit
caus
respiratori
infect
immunocompromis
patient
tabl
two
common
toxoplasma
gondii
strongyloid
stercorali
associ
consider
mortal
left
untreat
factor
promot
gondii
reactiv
includ
impair
tcell
immun
hiv
infect
hematolog
malign
hsct
sot
allogen
hsct
patient
posit
routin
blood
pcr
invas
diseas
risk
highest
seroposit
allogen
hsct
recipi
receiv
seroneg
graft
spars
data
avail
sot
recipi
suggest
lower
rate
risk
seroneg
recipi
acquir
gondii
seroposit
donor
depend
organ
type
highest
heart
transplant
data
patient
solid
tumor
scarc
toxoplasmosi
rare
report
patient
receiv
cancer
chemotherapi
immunocompromis
patient
fever
may
present
symptom
toxoplasmosi
may
progress
multipl
organ
failur
symptom
dissemin
toxoplasmosi
nonspecif
lung
central
nervou
system
often
involv
hepat
myocard
chorioretin
may
develop
featur
includ
lymphopenia
thrombocytopenia
rhabdomyolysi
lactat
dehydrogenas
elev
rare
case
isol
pulmonari
involv
present
may
mimic
interstiti
pneumonia
pjp
cmv
pneumonia
ct
may
show
lobar
consolid
groundglass
opac
thicken
interlobular
septa
serolog
test
unreli
immunocompromis
patient
may
use
previous
seroneg
patient
diagnosi
rest
pcr
blood
bal
fluid
sampl
microscop
examin
stain
bal
fluid
smear
studi
transplant
recipi
blood
pcr
sensit
treatment
consist
least
week
pyrimethamin
sulfadiazin
leucovorin
induct
follow
reduceddos
mainten
therapi
prognosi
dissemin
toxoplasmosi
involv
lung
grim
mortal
rate
icu
patient
streptococcu
stercorali
nematod
infect
human
skin
contact
larva
contain
soil
preval
vari
across
geograph
area
africa
south
america
asia
region
high
endem
million
peopl
may
infect
worldwid
industri
countri
strongyloidiasi
seen
immigr
tourist
militari
personnel
return
endem
area
us
cohort
kidney
transplant
candid
seroposit
stercorali
risk
factor
includ
walk
barefoot
engag
work
involv
skin
contact
soil
poor
sanitari
condit
streptococcu
stercorali
hyperinfect
syndrom
ssi
occur
chronic
infect
patient
becom
immunosuppress
notabl
receiv
steroid
immunosuppress
patient
develop
acut
strongyloidiasi
result
uncontrol
overprolifer
larva
dissemin
endorgan
includ
lung
liver
brain
infect
also
major
risk
factor
ssi
patient
present
nonspecif
respiratori
symptom
cough
fever
hemoptysi
asthma
arf
gastrointestin
symptom
includ
ileu
hemorrhag
chest
imag
may
reveal
nodular
reticular
alveolar
opac
may
reflect
combin
edema
hemorrhag
pneumon
gramneg
sepsi
common
complic
ssi
larval
invas
gut
wall
promot
bacteri
transloc
ssi
filariform
larva
may
found
bodili
fluid
sputum
bal
pleural
andor
periton
fluid
blood
eosinophilia
present
immunocompet
patient
may
absent
immunocompromis
patient
serolog
test
also
unreli
given
nonspecif
present
ssi
differenti
diagnosi
broad
includ
caus
pulmonari
hemorrhag
arf
sepsi
ivermectin
firstlin
treatment
treatment
continu
week
last
posit
stool
sampl
cover
complet
autoinfect
cycl
ssi
alway
fatal
left
untreat
report
mortal
rate
icu
patient
surviv
cancer
patient
improv
breakthrough
therapi
develop
rise
number
critic
ill
patient
immunocompromis
sever
bacteri
pneumonia
follow
viral
fungal
rare
parasit
infect
lead
caus
acut
hypoxem
respiratori
failur
icu
admiss
need
mortal
rate
high
knowledg
underli
immun
defici
thorough
clinicoradiolog
evalu
guid
diagnost
strategi
target
like
infecti
agent
decid
invas
versu
noninvas
approach
increasingli
sophist
noninvas
diagnost
tool
avoid
clinic
deterior
sometim
encount
invas
approach
avail
evalu
eg
realtim
pcr
nextgener
sequenc
transcriptom
could
allow
earlier
diagnosi
thu
improv
surviv
immunocompromis
patient
sever
pulmonari
infect
